| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10920017 | Radiotherapy and Oncology | 2005 | 6 Pages |
Abstract
Clinical outcomes are paramount in choice of fractionation scheme but are optimally considered in the light of economic implications. Overall cost differences between fractionation schedules may vary greatly from those incurred by the RT treatment centre alone. Ideally, such economic evaluations should be planned at the outset of a trial.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Christine A. Pollicino, Sandra L. Turner, Daniel E. Roos, Peter C. O'Brien,